The European Alliance of Associations for Rheumatology (EULAR) 2026 European Congress of Rheumatology

The novel small-protein IL-17 inhibitor izokibep demonstrates durable efficacy and a favourable safety profile over 52 weeks in patients with active psoriatic arthritis (PsA), with sustained improvements in joint, skin, and quality-of-life outcomes in a phase IIB/III study.

Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint. 

Treatment with baricitinib misses the noninferiority mark against tumour necrosis factor inhibitors (TNFi) in active rheumatoid arthritis (RA) patients at risk for venous thromboembolism (VTE) with high baseline disease activity, reports a study.

An extended-release formulation, HR091506, performs better than febuxostat immediate release in lowering urate levels in patients with gout and hyperuricaemia, as shown in a phase III trial.

Findings from the phase III RESILIENT study show that a sublingual formulation of cyclobenzaprine (CBP SL) may benefit individuals with fibromyalgia.